• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero®)

    Author(s)
    Ladhani, Shamez N
    Cordery, Rebecca
    Mandal, Sema
    Christensen, Hannah
    Campbell, Helen
    Borrow, Ray
    Ramsay, Mary E
    Griffith University Author(s)
    Slack, Mary P.
    Year published
    2014
    Metadata
    Show full item record
    Abstract
    Objectives: To assess the potential use of a protein-based meningococcal group B (MenB) vaccine (Bexsero®) in addition to antibiotic chemoprophylaxis for preventing secondary cases. Methods: Published studies on the risk of secondary meningococcal infections were used to estimate the numbers needed to vaccinate (NNV) with Bexsero® to prevent a secondary case in household and educational settings. Results: Most secondary cases occur within a few days of diagnosis in the index case. Unlike conjugate vaccines, early protection offered after a single dose of Bexsero® is likely to be low, particularly in young children, who are ...
    View more >
    Objectives: To assess the potential use of a protein-based meningococcal group B (MenB) vaccine (Bexsero®) in addition to antibiotic chemoprophylaxis for preventing secondary cases. Methods: Published studies on the risk of secondary meningococcal infections were used to estimate the numbers needed to vaccinate (NNV) with Bexsero® to prevent a secondary case in household and educational settings. Results: Most secondary cases occur within a few days of diagnosis in the index case. Unlike conjugate vaccines, early protection offered after a single dose of Bexsero® is likely to be low, particularly in young children, who are at higher risk of secondary infection. NNV was dependent on predicted meningococcal strain coverage, estimated onset of protection after one Bexsero® dose and estimated vaccine efficacy. Even in the most favourable scenario where we assume the vaccine is administered within 4 days of the index case and prevents 90% of cases occurring after 14 days, the NNV for household contacts was >1000. NNV in educational settings was much higher. Conclusions: The estimated NNV should be taken into account when deciding policy to recommend Bexsero® for close contacts of single cases in household or educational settings. Bexsero® may have a protective role in clusters and outbreaks
    View less >
    Journal Title
    Journal of Infection
    Volume
    69
    Issue
    5
    DOI
    https://doi.org/10.1016/j.jinf.2014.07.002
    Subject
    Public Health and Health Services not elsewhere classified
    Clinical Sciences
    Publication URI
    http://hdl.handle.net/10072/172005
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander